Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $116.2 million.

  • Coherus Oncology's Shares Outstanding (Weighted Average) rose 88.45% to $116.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.2 million, marking a year-over-year increase of 88.45%. This contributed to the annual value of $94.2 million for FY2023, which is 2129.67% up from last year.
  • Latest data reveals that Coherus Oncology reported Shares Outstanding (Weighted Average) of $116.2 million as of Q3 2025, which was up 88.45% from $116.1 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Shares Outstanding (Weighted Average) high stood at $116.2 million for Q3 2025, and its period low was $72.8 million during Q1 2021.
  • In the last 5 years, Coherus Oncology's Shares Outstanding (Weighted Average) had a median value of $83.3 million in 2023 and averaged $92.4 million.
  • Per our database at Business Quant, Coherus Oncology's Shares Outstanding (Weighted Average) crashed by 160.27% in 2022 and then soared by 4223.66% in 2024.
  • Over the past 5 years, Coherus Oncology's Shares Outstanding (Weighted Average) (Quarter) stood at $75.4 million in 2021, then rose by 2.89% to $77.6 million in 2022, then rose by 21.3% to $94.2 million in 2023, then rose by 22.35% to $115.2 million in 2024, then grew by 0.88% to $116.2 million in 2025.
  • Its last three reported values are $116.2 million in Q3 2025, $116.1 million for Q2 2025, and $115.9 million during Q1 2025.